表紙
市場調查報告書

遺傳性共濟失調症:開發中產品分析

Friedreich Ataxia - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 219741
出版日期 內容資訊 英文 108 Pages
訂單完成後即時交付
價格
Back to Top
遺傳性共濟失調症:開發中產品分析 Friedreich Ataxia - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 108 Pages
簡介

遺傳性共濟失調症是影響神經系統和心臟的遺傳性疾病,由於遺傳性缺陷基因所引起。症狀有運動失調、虛弱、痙攣、感覺障礙、骨骼異常、心臟障礙、糖尿病等。

本報告提供全球遺傳性共濟失調症治療用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

遺傳性共濟失調症概要

治療藥的開發

  • 遺傳性共濟失調症開發中產品:概要
  • 各企業開發中的治療藥
  • 大學/研究機關研究中的治療藥
  • 遺傳性共濟失調症:開發中產品一覽(各企業)
  • 遺傳性共濟失調症:研究中產品一覽(各大學/研究機關)

遺傳性共濟失調症:治療藥的評估

  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

遺傳性共濟失調症的開發作的企業

  • Adverum Biotechnologies Inc
  • BioMarin Pharmaceutical Inc.
  • Biovista Inc.
  • Cardero Therapeutics Inc
  • Catabasis Pharmaceuticals, Inc.
  • Forward Pharma A/S
  • Ixchel Pharma LLC
  • Pfizer Inc
  • ProQR Therapeutics NV
  • RaNA Therapeutics Inc
  • Reata Pharmaceuticals Inc
  • Retrotope Inc
  • Shire Plc
  • STATegics Inc
  • Voyager Therapeutics Inc

藥物簡介

遺傳性共濟失調症:開發暫停的產品

遺傳性共濟失調症:開發中止的產品

遺傳性共濟失調症相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11525IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Friedreich Ataxia - Pipeline Review, H2 2019, provides an overview of the Friedreich Ataxia (Central Nervous System) pipeline landscape.

Friedreich's ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties and diabetes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Friedreich Ataxia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Friedreich Ataxia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Friedreich Ataxia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Friedreich Ataxia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 3, 14, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Friedreich Ataxia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Friedreich Ataxia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Friedreich Ataxia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Friedreich Ataxia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Friedreich Ataxia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Friedreich Ataxia (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Friedreich Ataxia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Friedreich Ataxia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Friedreich Ataxia - Overview
  • Friedreich Ataxia - Therapeutics Development
  • Friedreich Ataxia - Therapeutics Assessment
  • Friedreich Ataxia - Companies Involved in Therapeutics Development
  • Friedreich Ataxia - Drug Profiles
  • Friedreich Ataxia - Dormant Projects
  • Friedreich Ataxia - Discontinued Products
  • Friedreich Ataxia - Product Development Milestones
  • Appendix

List of Tables

  • Table 1: Number of Products under Development for Friedreich Ataxia, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 4: Products under Development by Companies, H2 2019
  • Table 5: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 6: Products under Development by Universities/Institutes, H2 2019
  • Table 7: Number of Products by Stage and Target, H2 2019
  • Table 8: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 9: Number of Products by Stage and Route of Administration, H2 2019
  • Table 10: Number of Products by Stage and Molecule Type, H2 2019
  • Table 11: Friedreich Ataxia - Pipeline by Adverum Biotechnologies Inc, H2 2019
  • Table 12: Friedreich Ataxia - Pipeline by Agios Pharmaceuticals Inc, H2 2019
  • Table 13: Friedreich Ataxia - Pipeline by Amylyx Pharmaceutical Corp, H2 2019
  • Table 14: Friedreich Ataxia - Pipeline by BioElectron Technology Corp, H2 2019
  • Table 15: Friedreich Ataxia - Pipeline by Biointaxis SL, H2 2019
  • Table 16: Friedreich Ataxia - Pipeline by BioMarin Pharmaceutical Inc, H2 2019
  • Table 17: Friedreich Ataxia - Pipeline by Biovista Inc, H2 2019
  • Table 18: Friedreich Ataxia - Pipeline by Cardero Therapeutics Inc, H2 2019
  • Table 19: Friedreich Ataxia - Pipeline by Chondrial Therapeutics LLC, H2 2019
  • Table 20: Friedreich Ataxia - Pipeline by Exicure Inc, H2 2019
  • Table 21: Friedreich Ataxia - Pipeline by Fratagene Therapeutics Srl, H2 2019
  • Table 22: Friedreich Ataxia - Pipeline by Fulcrum Therapeutics Inc, H2 2019
  • Table 23: Friedreich Ataxia - Pipeline by Ixchel Pharma LLC, H2 2019
  • Table 24: Friedreich Ataxia - Pipeline by Jupiter Orphan Therapeutics Inc, H2 2019
  • Table 25: Friedreich Ataxia - Pipeline by Metro International Biotech LLC, H2 2019
  • Table 26: Friedreich Ataxia - Pipeline by Minoryx Therapeutics sl, H2 2019
  • Table 27: Friedreich Ataxia - Pipeline by Panorama Research Inc, H2 2019
  • Table 28: Friedreich Ataxia - Pipeline by Pfizer Inc, H2 2019
  • Table 29: Friedreich Ataxia - Pipeline by PTC Therapeutics Inc, H2 2019
  • Table 30: Friedreich Ataxia - Pipeline by Reata Pharmaceuticals Inc, H2 2019
  • Table 31: Friedreich Ataxia - Pipeline by Retrotope Inc, H2 2019
  • Table 32: Friedreich Ataxia - Pipeline by Seelos Therapeutics, Inc., H2 2019
  • Table 33: Friedreich Ataxia - Pipeline by STATegics Inc, H2 2019
  • Table 34: Friedreich Ataxia - Pipeline by Voyager Therapeutics Inc, H2 2019
  • Table 35: Friedreich Ataxia - Dormant Projects, H2 2019
  • Table 36: Friedreich Ataxia - Discontinued Products, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Friedreich Ataxia, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Targets, H2 2019
  • Figure 5: Number of Products by Stage and Targets, H2 2019
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
  • Figure 10: Number of Products by Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Molecule Types, H2 2019
Back to Top